A scoreboard, not a league table
Before anyone ranks brands, name the tools. ED trials do not eyeball a bedroom. They use the same questionnaires.
The workhorse is the International Index of Erectile Function, especially the erectile-function domain, IIEF-EF. Men answer items about firmness and reliability. The domain sums to a severity score. Trials also log the Sexual Encounter Profile. SEP2 asks whether penetration happened. SEP3 asks whether the erection lasted long enough to finish. Those three numbers are how the whole class is judged, so vardenafil's package can be laid next to sildenafil and tadalafil without inventing a new yardstick.
In the pivotal placebo-controlled work, vardenafil moved all three. IIEF-EF rose. Successful penetration attempts climbed. More encounters ended with an erection that lasted through intercourse. Effects grew with dose. That is a strong case for the drug as a drug. It is not a case that the drug won a tournament. Mechanism detail stays in the vardenafil medicine file. This page files endpoints, hard groups, and the QT row.
Four fixed-dose trials. 2431 men. Three months.
| North American general ED, 3 months | Placebo | 5 mg | 10 mg | 20 mg |
|---|---|---|---|---|
| SEP2 (penetration) | 52% | 65% | 75% | 80% |
| SEP3 (finished intercourse) | 32% | 51% | 64% | 65% |
The US label's main efficacy package is four double-blind, randomized, placebo-controlled, fixed-dose, parallel, multicenter trials. 2431 men, ages 20 to 83, mean age 57. Two trials in a general ED population. One in diabetes. One after prostatectomy. Doses in those studies were 5, 10, and 20 mg - not 2.5. The 2.5 mg face is a labeled interaction and metabolism rung, not a pivotal efficacy arm. Levitra was taken as needed, without regard to meals, and primary endpoints were read at three months.
Mean baseline IIEF-EF in those trials was 11.8 on a 0-30 scale - moderate-to-severe territory, not a mild-nuisance sample. Vardenafil at 5, 10, and 20 mg improved EF domain, SEP2, and SEP3 versus placebo across age bands and across reported race groups. In the North American general-ED trial, SEP2 at three months was 65% on 5 mg, 75% on 10 mg, and 80% on 20 mg, against 52% on placebo. SEP3 was 51%, 64%, and 65% against 32% on placebo. The European general-ED trial lined up the same way.
Read those percentages as 'more yes answers than placebo,' not as a promise that four out of five nights will be perfect. Placebo already cleared penetration about half the time. The drug's job was the gap, and the gap was real.
The hard files: diabetes and nerve-sparing surgery
Mild ED answers almost any PDE5 tablet. The test is the groups where vessels and nerves are already damaged.
The diabetes trial enrolled 439 men, mean age 57, fixed doses 10 and 20 mg. High glucose injures the small vessels and nerves that drive erection, so every drug in this class returns a smaller absolute effect here. Vardenafil still moved the scoreboard. SEP2: 61% on 10 mg and 64% on 20 mg against 36% on placebo. SEP3: 49% and 54% against 23%. File that as 'works, ceiling lower,' not as a vardenafil flaw. Better glucose control helps any tablet in the class. A smaller gap than a non-diabetic man's is disease burden, not a failed molecule.
The post-prostatectomy trial enrolled 427 men, mean age 60, again 10 and 20 mg. SEP2: 47% and 48% against 22% on placebo. SEP3: 37% and 34% against 10%. Those numbers only make sense if erection nerves were spared. If the nerves are gone, no PDE5 tablet replaces missing wiring. Setting that expectation is part of honest prescribing, not a footnote. How the molecule reached market is in the Wuppertal-to-Levitra origin file. How you time a dose is not this page's job.
Levitra 2.5-5 mg reviews are a ladder, not a ranking
| File | Labeled vardenafil move | Why the rung changes |
|---|---|---|
| Most adults | Start 10 mg ~60 min before sex; 5-20 mg range | Titrate to effect and tolerability |
| Age 65+ | Consider 5 mg start | Higher exposure with age |
| Child-Pugh B liver | Start 5 mg; cap 10 mg | Clearance falls, levels rise |
| Strong CYP3A4 inhibitors | Cap often 2.5 mg (ritonavir: 2.5 mg / 72 h) | AUC can jump many-fold |
| Stable on an alpha-blocker | Lowest labeled start, separated in time | Additive hypotension |
| Max frequency | Once per day | No extra benefit past that |
Film-coated tablets come at 2.5, 5, 10, and 20 mg. Most men work 5-10-20. The label starts most adults at 10 mg about an hour before sex, then moves to 20 or down to 5. Trial dose response is real: 20 beat 10, which beat 5, on the same endpoints. Climbing because a forum said 20 is 'the real dose' is not evidence. Stay at the lowest rung that reliably works.
The ladder bends for named files. Age 65 and over: consider a 5 mg start because Cmax and AUC run about 34% and 52% higher. Moderate hepatic impairment (Child-Pugh B): start 5 mg, do not exceed 10 mg. Strong CYP3A4 inhibitors force steep cuts - down to 2.5 mg, and with ritonavir no more than 2.5 mg in 72 hours. Alpha-blockers need a low, time-separated start so two blood-pressure drops do not stack. None of that is optional fine print. It is how a proven tablet stays a proven tablet.
The QT row: 59 men, 10 mg, 80 mg, moxifloxacin
If one labeled fact separates vardenafil from its siblings, it is electrical timing on the tracing - not bench potency.
A single-dose, double-blind, randomized, placebo- and active-controlled crossover study put vardenafil in 59 healthy men aged 45-60. Therapeutic 10 mg film-coated and supratherapeutic 80 mg (four times the highest recommended dose) were compared with moxifloxacin 400 mg, the usual positive control because it lengthens QT. The tracing was read at one hour, near typical peak. Therapeutic and supratherapeutic vardenafil and moxifloxacin produced similar QTc increases. The study was not built for a statistical bake-off between drugs or doses. The clinical meaning of those milliseconds is still called unknown on the label.
Heart rate rose a little - about 5 beats per minute after 10 mg, about 6 after 80 mg. The 80 mg arm was chosen because it covers concentrations seen when a low 5 mg dose sits with ritonavir 600 mg twice daily, the ugliest CYP3A4 pile-up in the interaction table. That is why a 2.5 mg cap exists on ritonavir. The QT row and the interaction row are the same pile of exposure.
Additive minutes: the gatifloxacin add-on
| Feature | Vardenafil on the evidence | Against the class |
|---|---|---|
| IIEF-EF, SEP2, SEP3 | Strong, dose-dependent vs placebo | Comparable to sildenafil and tadalafil |
| In-vitro potency | Holds PDE5 at lower concentration | Does not translate to a better night |
| Onset / duration | About 30-60 min / about 4-5 h | Sildenafil-like window, not tadalafil's ~36 h |
| QT interval | Modest labeled prolongation; additive with another QT drug | Clearest QT row in the class |
| Who walks away | Congenital long QT; Class IA / III antiarrhythmics | Siblings lack this veto |
| Nitrates | Absolute contraindication | Same veto for the whole class |
A separate postmarketing study in 44 healthy volunteers gave 10 mg Levitra alone, gatifloxacin 400 mg alone, and both together. Placebo-subtracted QTcF change: about 5 msec for vardenafil (90% CI 2-8), about 4 msec for gatifloxacin (90% CI 1-7), about 9 msec when stacked (90% CI 6-11). Additive. Not synergistic magic. Still a reason the label tells you to think before you stack two QT-active drugs.
For a healthy man with a normal heart, this is a labeled caution, not a practical scare. It becomes a decision in two stamped situations: congenital long-QT syndrome - avoid vardenafil - and men on Class IA antiarrhythmics (quinidine, procainamide) or Class III agents (amiodarone, sotalol). In those files I pick another PDE5 inhibitor. Sildenafil and tadalafil do not carry this signal to the same degree. That is the fingerprint. It should move prescriptions more than any 'more potent' slide ever should. Clock and food, which can change peak and therefore the hour you care about, sit in the timing, fat, and grapefruit card.
What the evidence does not crown
Three drugs, one mechanism, three personalities. Sildenafil is the original with a food quirk - see the sildenafil medicine file. Tadalafil is long-acting and untethers the weekend - see the tadalafil medicine file. Vardenafil is the shorter middle option with the QT caveat. Efficacy is a near-tie. Duration, food, cost, and the QT row decide choices. Want spontaneity across two days? Tadalafil's duration usually wins. On-demand need and a normal tracing? Any of the three can fit. Long QT or a Class IA / III drug? Step off vardenafil.
Summed up: vardenafil is well proven and easy to oversell. It improves erectile function on validated endpoints, climbs a clean 5-to-20 mg ladder, and holds up in diabetes and after nerve-sparing surgery. Lab potency is talk. The decision-grade fact is the QT row. Underneath sits the nitrate contraindication for the entire class - unchanged, non-negotiable. How the molecule reached the stamp is in the Wuppertal origin file. How you swallow it without a greasy plate ruining the peak is in the timing card.